Erica R. Tobin

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> Mutations

Katharine Yen, Jeremy Travins, Fang Wang et al. · Cancer Discovery · 2017 · 458 citations · Full text

Medicine, Oncology, Pharmacology +17

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers

Janeta Popovici-Müller, René M. Lemieux, Erin Artin et al. · ACS Medicinal Chemistry Letters · 2018 · 444 citations · Full text

Medicine, Molecular Biology, Oncology +14

The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development

François Lemonnier, Rob A. Cairns, Satoshi Inoue et al. · Proceedings of the National Academy of Sciences · 2016 · 119 citations · Full text

Medicine, Genetics, Oncology +16

The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors

Louise Cadzow, Jehrod Brenneman, Erica R. Tobin et al. · Cancer Research · 2024 · 48 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

<i>Idh1</i> mutations contribute to the development of T-cell malignancies in genetically engineered mice

Zhenyue Hao, Rob A. Cairns, Satoshi Inoue et al. · Proceedings of the National Academy of Sciences · 2016 · 23 citations · Full text

Medicine, Molecular Genetics, Oncology +14